



edap tms
Bringing New Horizons to Therapy

EDAP TMS S.A.
Investor Relations Department
4 Rue du Dauphine
Vaulx-en-Velin 69120
France

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: EDAP

Last Trade:	2.80
Trade Time:	3:59 PM ET May 26, 2017
Change:	0.00 (+0.089%)
Day Range	2.75 - 2.85
52-Week Range	2.25 - 3.62
Volume	25,224

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 22, 2017
[EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate](#)
- May 17, 2017
[EDAP TMS SA Reports First Quarter 2017 Results](#)
- May 11, 2017
[EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2017](#)
- May 2, 2017
[EDAP TMS SA to Report First Quarter 2017 Financial Results on May 17, 2017](#)
- Apr 3, 2017
[EDAP Achieves 63% Growth in HIFU Revenue in 2016](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Apr 3, 2017
[Annual Report for Foreign Private Issuers \(20-F\)](#)